Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 21673

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 20571

Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Disease Site: Lymphoma, Non-Hodgkin's Lymphoma
PI: Locke, Frederick

Clinical Trial 90016

Disease Site: Other Hematopoietic
PI: Sandoval-Sus, Jose

Clinical Trial 22464

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)
Disease Site: Thyroid, Head & Neck, Mouth, lip, nasal cavity
PI: Agosto Salgado, Sarimar

Clinical Trial 21676

Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases
Disease Site: Breast
PI: Ahmed, Kamran

Clinical Trial 23090

Disease Site: Lung
PI: Pellini, Bruna

Clinical Trial 22463

SPECT-CT Guided Elective Contralateral Neck Treatment (Select) For Patients With Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial.
Disease Site: Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Danan, Deepa

Clinical Trial 23101

Disease Site: Other Hematopoietic
PI: Fernandez, Hugo

Clinical Trial 23303

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Disease Site: Prostate
PI: Yamoah, Kosj

Clinical Trial 23254

A Phase 1/1b Open-Label, Dose-Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor BH-30236 in Adults with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Disease Site: Acute Leukemia (ALL, AML), Myeloid and Monocytic Leukemia
PI: Xie, Zoey (Zhuoer)

Clinical Trial 21731

A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 21193

Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)